Scannell Olya, O'Neill Valerie, Dunne Mary, Baily Caroline, Salih Amira, Cunningham Moya, Horgan Noel
Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland.
St Luke's Hospital, Dublin, Ireland.
Ocul Oncol Pathol. 2020 Mar;6(2):99-106. doi: 10.1159/000501692. Epub 2019 Aug 22.
Uveal melanoma and its treatment can influence the physical and psychological well-being of patients in a way that differs from other cancers. Factors influencing quality of life (QOL) include visual impairment, changes in appearance, day-to-day functioning, ocular discomfort, and worry regarding disease recurrence.
We aimed to study both general and disease-specific QOL in uveal melanoma patients in Ireland and compare QOL between a plaque radiotherapy group and an enucleation treatment group. This information was sought to enhance our understanding of QOL issues for uveal melanoma patients, in the context of improving care and providing appropriate psychosocial support.
The European Organisation for Research and Treatment of Cancer (EORTC) QOL questionnaires QLQ-C30 and QLQ-OPT30 were completed by patients with uveal melanoma treated by enucleation or brachytherapy.
138 of 206 patients completed the questionnaires. There was no significant difference in QOL scores between treatment groups. Thirty-two percent of patients reported concerns about tumour recurrence elsewhere in the body. The brachytherapy group had a significantly higher "role functioning" score ( = 0.030). Enucleation patients were more likely to have problems with appearance ( < 0.0005). Younger patients (12-54 years of age) were more likely to report headaches ( < 0.0005) and problems with reading ( = 0.042), and they had a lower cognitive functioning score ( = 0.003) than those aged ≥55 years.
There was no significant difference in reported QOL between treatment groups. Our data identified a number of vulnerable patient subgroups. By anticipating which patients are more likely to suffer in terms of certain aspects of their QOL, we are better able to provide appropriate and timely psychosocial support.
葡萄膜黑色素瘤及其治疗对患者身心健康的影响方式与其他癌症不同。影响生活质量（QOL）的因素包括视力损害、外貌变化、日常功能、眼部不适以及对疾病复发的担忧。
我们旨在研究爱尔兰葡萄膜黑色素瘤患者的总体生活质量和疾病特异性生活质量，并比较斑块放射治疗组和眼球摘除治疗组之间的生活质量。获取这些信息是为了在改善护理和提供适当心理社会支持的背景下，增进我们对葡萄膜黑色素瘤患者生活质量问题的理解。
接受眼球摘除术或近距离放射治疗的葡萄膜黑色素瘤患者完成了欧洲癌症研究与治疗组织（EORTC）的生活质量问卷QLQ-C30和QLQ-OPT30。
206例患者中有138例完成了问卷。治疗组之间的生活质量得分无显著差异。32%的患者报告担心身体其他部位出现肿瘤复发。近距离放射治疗组的“角色功能”得分显著更高（P = 0.030）。眼球摘除患者在外貌方面更可能存在问题（P < 0.0005）。年轻患者（12 - 54岁）比≥55岁的患者更可能报告头痛（P < 0.0005）和阅读问题（P = 0.042），且认知功能得分更低（P = 0.003）。
治疗组之间报告的生活质量无显著差异。我们的数据确定了一些易受影响的患者亚组。通过预测哪些患者在生活质量的某些方面更可能遭受痛苦，我们能够更好地提供适当和及时的心理社会支持。
